Publications by authors named "A Martinez-Torron"
Article Synopsis
- * A study involving 594 patients assessed various treatment regimens and found that those using FOLFOX with trastuzumab had a significantly longer median exposure to the drug and better overall survival rates compared to traditional ToGA regimens.
- * Results indicated that patients with HER2 IHC 3+ tumors responded better to treatment, while FOLFOX-trastuzumab showed promising outcomes, especially for subtypes traditionally less responsive to trastuzumab, warranting further investigation. *
Background: Advanced esophageal adenocarcinoma (EAC) is generally treated similarly to advanced gastroesophageal junction (GEJ-AC) and gastric (GAC) adenocarcinomas, although GAC clinical trials rarely include EAC. This work sought to compare clinical characteristics and treatment outcomes of advanced EAC with those of GEJ-AC and GAC and examine prognostic factors.
Patients And Methods: Participants comprised patients with advanced EAC, intestinal GEJ-AC, and GAC treated with platin and fluoropyrimidine (plus trastuzumab when HER2 status was positive).
Objective: The aim of the study was to describe the type of vaccines administered in the Vaccine Unit at a reference hospital. Calculate the overall and specific reporting rate of adverse reactions.
Methods: Retrospective observational study for the period between November 2014 and November 2017, on patients who developed an adverse drug reaction (ADR) after the administration of a vaccine and who were notified to the Spanish Pharmacovigilance System.
Background: The optimal duration of first-line chemotherapy for patients with advanced gastric cancer is unknown. Diverse clinical trials have proposed different strategies including limited treatment, maintenance of some drugs, or treatment until progression.
Method: The sample comprises patients from the AGAMENON multicenter registry without progression after second evaluation of response.